195 related articles for article (PubMed ID: 15539918)
1. Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.
Santini D; Vincenzi B; Perrone G; Rabitti C; Borzomati D; Caricato M; La Cesa A; Grilli C; Verzì A; Coppola R; Tonini G
Oncology; 2004; 67(2):135-42. PubMed ID: 15539918
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
Kamoshida S; Matsuoka H; Ishikawa T; Maeda K; Shimomura R; Inada K; Tsutsumi Y
Jpn J Clin Oncol; 2004 Oct; 34(10):594-601. PubMed ID: 15591457
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer.
Aguiar S; Lopes A; Soares FA; Rossi BM; Ferreira FO; Nakagawa WT; Carvalho AL; Filho WJ
Eur J Surg Oncol; 2005 Oct; 31(8):863-8. PubMed ID: 15923105
[TBL] [Abstract][Full Text] [Related]
6. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
Noda E; Maeda K; Inoue T; Fukunaga S; Nagahara H; Shibutani M; Amano R; Nakata B; Tanaka H; Muguruma K; Yamada N; Yashiro M; Ohira M; Ishikawa T; Hirakawa K
Hepatogastroenterology; 2012; 59(113):130-3. PubMed ID: 21940361
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
[TBL] [Abstract][Full Text] [Related]
9. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
10. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
13. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
15. Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur.
Grau JJ; Domingo-Domenech J; Morente V; Pera M; Garcia-Valdecasas JC; Fuster J; Bombí A; Mellado B; Albanell J; Gascón P
Oncology; 2004; 66(3):226-33. PubMed ID: 15218314
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
18. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information.
Ohrling K; Edler D; Hallström M; Ragnhammar P; Blomgren H
J Clin Oncol; 2005 Aug; 23(24):5628-34. PubMed ID: 16009948
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
Edler D; Kressner U; Ragnhammar P; Johnston PG; Magnusson I; Glimelius B; Påhlman L; Lindmark G; Blomgren H
Clin Cancer Res; 2000 Feb; 6(2):488-92. PubMed ID: 10690528
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
Oi K; Makino M; Ozaki M; Takemoto H; Yamane N; Nakamura S; Ikeguchi M; Kaibara N
Anticancer Res; 2004; 24(1):273-9. PubMed ID: 15015608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]